Skip to main content
SpringerLink
Log in

Letter to the Editor: What to Measure in Autism Drug Trials

  • Letter to the Editor
  • Published:
Journal of Autism and Developmental Disorders Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

REFERENCES

  • Chez, M. G., Buchanan, C. P., Bagan, B. T., Hammer, M. S., Mc-Carthy, K. S., Ovrutskaya, I., Nowinski, C. V., & Cohen, Z. S. (2000). Secretin and autism: A two-part clinical investigation. Journal of Autism and Developmental Disorders, 30, 87-94.

    Google Scholar 

  • Horvath, K., Stefanatos, G., Sokolski, K. N., Wachtel, R. C., Nabors, L., & Tildon, J. T. (1998). Improved social and language skills after secretin administration in patients with autistics spectrum disorders. Journal of the Association for Academic Minority Physicians, 9, 9-15.

    Google Scholar 

  • Lightdale, J. R., Hayer, C., Duer, A., Lind-White, C., Siegel, B., Elliott, G. R., & Heyman, M. B. (2000). Analysis of formal language testing following an open-label trial of secretin in children with autism. Pediatric Research, 47, 29A (Abstr. 169).

    Google Scholar 

  • Sandler, A. D., Sutton, K. A., DeWeese, J., Girardi, M. A., Sheppard, V., & Bodfish, J. W. (1999). Lack of benefit of a single dose of synthetic human secretin in the treatment of autism and pervasive developmental disorder. New England Journal of Medicine, 341, 1801-1806.

    Google Scholar 

Download references

Rights and permissions

Reprints and permissions

About this article

Cite this article

Letter to the Editor: What to Measure in Autism Drug Trials. J Autism Dev Disord 31, 361–362 (2001). https://doi.org/10.1023/A:1017339106682

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1023/A:1017339106682

Keywords

Search

Navigation